|
|
Article: Study an Overview of the Key Companies Involved In the HIV Pipeline, Including an Analysis of the New Corporate Alliances.
- Article from:
- AIDS Weekly
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Research and Markets (http://www.researchandmarkets.com/research/f9e8fd/pipeline_insight) has announced the addition of the "Pipeline Insight: HIV - The Age of Convenience" report to their offering (see also Research and Markets).
Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard fixed dose combination for treatment-naive patients. Addressing Atripla's shortcomings, Datamonitor expects this product to dominate the market.
Scope
In-depth analysis of Phase II and III ...